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Abstract  
This review will focus on the proposed second mode of testos-
terone action (now termed non-genomic) that appears to occur 
independently of the traditional transcriptional mechanism in 
mammalian skeletal muscle cells which may enhance skeletal 
muscle contractile properties. This mechanism of testosterone 
action differs from the traditional pathway, originating at the 
cell membrane, having a rapid onset of action, requiring second 
messengers to execute its effects and is insensitive to inhibitors 
of traditional androgen receptor action, transcription and protein 
synthesis. Importantly, unlike the traditional action of testoster-
one in skeletal muscle, this non-genomic pathway is shown to 
have a direct acute effect on calcium-dependent components 
important for the contractile process. The changes within the 
contractile apparatus may enhance the ability of the muscle to 
produce explosive power during athletic performance. Rapid 
increases in Inositol triphosphate mass and calcium release from 
the sarcoplasmic reticulum have been reported in rodent skeletal 
muscle cells, and a rapid androgen (dihydrotestosterone)-
induced increase in peak force production has been recorded in 
intact rodent skeletal muscle fibre bundles while showing in-
creases in the activity of the Ras/MAP/ERK mediated pathway. 
Because the non-genomic action of testosterone is enhanced 
during increases in exposure to testosterone and is acute in its 
action, implications for athletic performance are likely greater in 
females than males due to  natural fluctuations in circulating 
testosterone levels during the female menstrual cycle, reproduc-
tive pathology, and changes induced by  hormonal contraceptive 
methods. Research should be undertaken in humans to confirm a 
pathway for non-genomic testosterone action in human skeletal 
muscle. Specifically, relationships between testosterone fluctua-
tions and physiological changes within skeletal muscle cells and 
whole muscle exercise performance need to be examined.  
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Introduction 
 
During exercise, the endocrine system secretes hormones 
into the bloodstream to regulate metabolism (McKeever, 
2002; Mastorakos et al., 2005)  and maintain the integrity 
of the body’s internal environment. Therefore the control 
of hormone secretion must be complex and sensitive to 
adapt quickly to changing biological stresses within the 
body during exercise. Testosterone is an anabolic steroid 
hormone that is found in the bloodstream in 3 forms; 
strongly bound to sex hormone binding globulin (SHBG) 
(~70%), weakly bound to albumin (~30%) and unbound 
(~0.5-3%). Traditionally, the physiological function of 
testosterone in skeletal muscle tissue is the maintenance 
and increase of skeletal muscle mass (hypertrophy) 
through genomic (long-term, transcriptional) mechanisms 
and the subsequent indirect increase in muscle strength 
(Cardinale and Stone, 2006; Griggs et al., 1989). How-
ever, steroid hormones including testosterone are now 
shown to elicit rapid actions (within seconds to minutes) 
in a number of cell types (Benten et al., 1997; 1999a; 
Ceballos et al., 1999; Estrada et al., 2003; Furukawa and 
Kurokawa, 2008; Hamdi and Mutungi, 2010; Jones et al., 
2004; Waldkirch et al., 2008) through non-genomic 
mechanisms (short-term, non-transcriptional) (Benten et 
al., 1999b). The complex interaction of acute and long 
term steroid adaptation has however, yet to be described. 
While testosterone’s significant genomic action in skeletal 
muscle is well described, (Bhasin et al., 2005; Sinha-
Hikim et al., 2002; 2003; Urban et al., 1995) little atten-
tion has been directed towards such non-genomic actions 
of testosterone in skeletal muscle. This article will discuss 
a mode of non-genomic action in skeletal muscle and 
proposed implications for sporting performance specifi-
cally for female athletes. 
 
What are non-genomic steroid actions? 
Non-genomic actions of steroid hormones are those ster-
oid mediated actions in which gene transcription is not 
directly implicated (shown through  insensitivity to in-
hibitors of transcription and protein synthesis), involves 
second messenger participation  and are rapid in action 
(within seconds to minutes). As described further in this 
review, non-genomic actions differentiate themselves 
from genomic mechanisms in the first instance by the 
binding of the steroid to an androgen receptor located on 
the cell-membrane or by linking with a plasma membrane 
receptor associated with a Pertussis toxin (PTX)-sensitive 
G protein (Vicencio et al., 2006) rather than binding with 
the traditional androgen receptor in the cytoplasm of the 
cell before being translocated into the nucleus. Unlike the 
genomic effects of steroid hormones, non-genomic effects 
require the constant presence of the hormone. Once the 
hormone subsides from the tissue, so too will the non-
genomic effects.  
Evidence for a non-traditional testosterone action 
has been documented regularly in tissues other than skele-
tal muscle.  In the early 1990s, a rapid effect of testoster-
one on calcium mobility in T-cells, that was initiated at 
the cell membrane was reported (Benten et al., 1999b), 
suggesting there was an alternative rapid biological re-
sponse to testosterone. Similarly, cardiac myocytes from 
adult rats exposed to testosterone rapidly (1-7 minutes) 
induced an increase in levels of intracellular calcium 
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released from intracellular stores through Inositol 
trisphosphate (IP3) receptors. This calcium response was 
not linked with the intracellular androgen receptor, but 
instead through activation of a plasma membrane receptor 
associated with a (PTX)-sensitive G protein (Vicencio et 
al., 2006). Similarly again, testosterone rapidly stimulated 
increases in calcium concentration in rat osteoblasts 
(within 5 s via enhanced calcium influx) and increased 
calcium mobilisation from the endoplasmic reticulum, as 
well as increasing IP3 formation within 10 s (Lieberherr 
and Grosse, 1994).  IP3 is used for signal transduction in 
biological cells via the release of calcium from the endo-
plasmic reticulum via the IP3 receptor (IP3R). Testoster-
one appears to exert these rapid actions through an uni-
dentified G-protein (guanine nucleotide-binding proteins 
communicate signals from hormones extracellular that 
then regulate changes intracellular) located on the cell 
membrane (Benten et al., 1999a; Vicencio et al., 2006). 
Rapid actions of testosterone in skeletal muscle 
have been less researched compared with other tissues 
such as cardiac muscle and bone (Benten et al., 1997; 
1999a) as outlined above. However, the few papers inves-
tigating non-genomic testosterone action in skeletal mus-
cle suggest testosterone is capable of producing similar 
rapid (within 2 min) effects in skeletal muscle cells 
(Estrada 2000; 2003; Hamdi and Mutungi, 2010). To date, 
non-genomic testosterone action in skeletal muscle has 
only been investigated in isolated rodent cells and fibre 
bundles, with most evidence originating from two studies 
by Estrada et al (Estrada et al., 2000; 2003). These two 
studies isolated myotubes and achieved a response to 100 
nM of testosterone in 70% of cells. Supraphysiological 
levels of testosterone (100 nM) at the single-cell level in 
primary myotubes induced a relatively fast (<2 min) tran-
sient increase in intracellular calcium, which was fre-
quently accompanied by oscillations and a transient in-
crease in the mass of IP3 to threefold the basal levels 
within 45 s. Both unbound and albumin-bound testoster-
one initiated this non-genomic action. These results are 
similar to those previously identified in other tissue cells 
(cardiac myocytes, T-Cells, osteoblasts). These results 
provided support for a G-protein-linked receptor at the 
plasma membrane, and an IP3/calcium, Ras/MEK/ERK 
mediated pathway. ERK1/2 increased in response to tes-
tosterone in a transient and dose-dependent (50-100nM) 
manner, while G-protein inhibitors blocked the fast rise in 
calcium and IP3 and thus the fast effect of testosterone. 
Therefore, the signal transduction mechanisms of non-
genomic actions within skeletal muscle are likely regu-
lated by second messengers such as intracellular calcium 
and IP3 (Estrada et al., 2000; Estrada et al., 2003). These 
non-genomic signal pathways have been previously iden-
tified in the action of testosterone, aldosterone, (Estrada et 
al., 2000) and 17-β-estradiol (Morley and Whitfield et al., 
1992)  and are outlined in Figure 1.   
The only study of rapid steroid action in intact 
skeletal muscle fibres was recently published by Hamdi 
and Mutangi (2010). This study used intact isolated skele-
tal muscle fibres from the extensor digitorum longus 
(predominantly fast-twitch) and soleus (predominantly 
slow twitch) muscles of adult male and female mice. Like 
the previous studies, this study used formerly published 
methods to investigate the effects of steroid hormones on 
maximum isometric force. Physiological concentrations 
of dihydrotestosterone (DHT) (630 pg·ml-1), significantly 
increased force produced in both twitch and titanic con-
tractions in fast twitch fibres. A significant 24% increase 
in maximum isometric tension in fast twitch fibres
 
 
 
 
 
Figure 1. Possible non-genomic pathway/action of testosterone in skeletal muscle. 
Testosterone (T) attaches to a traditional androgen receptor (AR) located at the cell membrane, coupled with a PTX-sensitive G-protein that 
activates phospholipase C (PLC). This in turn increases IP3 levels, which are liberated and diffuse to receptors (IP3R) on the sarcoplasmic 
reticulum (SR). This in turn increases intracellular calcium levels through the release of calcium from the SR. A possible calcium-induced 
activation of the Ras/ERK phosphorylation cascade may occur, resulting in transcription of DNA, which is then expressed as proteins. 
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in male mice and a 30% increase in female mice, though 
not statistically different from each other, suggests it may 
be appropriate to investigate potential gender differences 
in non-genomic steroid action. Testosterone however, had 
no effect on either twitch or tetanic contractions in either 
fast or slow twitch muscle in intact rodent muscle fibre 
bundles (Hamdi and Mutungi, 2010). In parallel with the 
increases in maximum isometric force seen with exposure 
to DHT, physiological concentrations of DHT increased 
phosphorylation of ERK1/2 by 2-3 fold in both fibre types 
adding support for a non-genomic androgen 
RAS/MAP/ERK mediated pathway. Testosterone in-
creased ERK1/2 phosphorylation in slow twitch fibres 
only.  
While the aforementioned animal studies provide 
evidence for a non-genomic mechanism, the ability to 
deduce human effects from rodent studies is unclear. It is 
therefore important that human research be undertaken to 
provide evidence for a non-genomic steroid action in 
human skeletal muscle. Based on the current 
understanding of non-genomic testosterone action, we 
suggest that testosterone may be able to produce an 
increase in intracellular calcium levels and calcium 
mobility within the human skeletal muscle cell. This may 
increase the sensitivity of the contractile elements to cal-
cium, which could increase the speed of myosin head 
binding and/or the force at which the myosin head pulls, 
such that more force is produced per contraction. 
Combined, these effects would likely result in greater 
whole muscle power production (refer to Figure 1).  
Although current research provides a substantiated basis 
for this theory (Estrada et al., 2000; 2003; Hamdi and 
Mutungi, 2010), it is vital that research in human skeletal 
muscle is undertaken to provide evidence to support both 
the molecular and physiological undertones of this theory. 
Until further research is undertaken, implications for 
athletic performance will remain speculative. 
 
Testosterone and athletic performance 
From testosterone supplementation studies in males (3 
mg·kg-1·wk-1 for 12 wk) (Griggs et al., 1989) and (600 
mg·wk-1 for 10 wk), (Bhasin et al., 1996) the traditional 
(transcriptional) action of testosterone demonstrates the 
ability to increase protein synthesis (27%), (Griggs et al., 
1989) fat free mass (6.1 ± 0.6 kg ), (Bhasin et al., 1996) 
muscle mass (20%), (Griggs et al., 1989) muscle size 
(triceps brachii 501 ± 104 mm2, quadriceps 1174 ± mm2) 
(Bhasin et al., 1996) and strength (bench press 22 ± 2 kg, 
squat 38 ± 4 kg) (Bhasin et al., 1996). Subsequently tes-
tosterone was officially listed as a banned substance in 
athletic events. While chronic testosterone supplementa-
tion can increase strength; (Bhasin et al., 1996) power or 
counter-movement jump height has also been shown to 
positively correlate with acute natural levels (0.62 ± 0.06 
ng·ml-1 and 6.49 ± 0.37 ng·ml-1) of testosterone (r = 0.061, 
p<0.001) in female and male elite athletes, respectively 
(Cardinale and Stone, 2006). Natural basal testosterone 
levels and counter-movement jump height are higher in 
explosive athletes, such as sprinters, and lowest in endur-
ance athletes such as cross-country skiers (Bosco, 1998). 
Given testosterone’s dual mechanisms (i.e., genomic and 
non-genomic action), natural testosterone levels may 
prove to be more important in the ability to produce acute 
explosive power; a variable that is a determinant of per-
formance in sprint, jumping and throwing events (Bourdin 
et al., 2010; Hori et al., 2008; Sleivert and Taingahue, 
2004; Van Ingen Schenau et al., 1990) than previously 
thought. 
 
Fatigue hypothesis: How the non-genomic action of 
testosterone may counteract fatigue 
Calcium is an important metabolite in muscle contraction, 
with both the concentration surrounding the myofilaments 
and the sensitivity of the myofilaments to calcium impor-
tant for the production of force by the individual cross-
bridges (maximum calcium activated force). Intensive and 
repetitive contraction of skeletal muscle causes a decline 
in peak performance (i.e. fatigue) characterized by re-
duced force production, decreased shortening velocity, 
and delayed relaxation of the muscle following contrac-
tion (Bigland-Ritchie et al., 1979; Edman and Mattiazzi, 
1981; Haan et al., 1989; Jones et al., 1979; Milner-Brown 
and Miller, 1986; Westerblad and Lännergren, 1991; 
Cheng and Rice, 2010). One principal theory of skeletal 
muscle fatigue is characteristic changes in calcium regula-
tion and sensitivity that occur during the decline in per-
formance (Kabbara and Allen, 1999). 
Previous research provides evidence that during fa-
tiguing muscle contraction there is a decline in calcium 
transport;  a decline in sarcoplasmic reticulum calcium 
release (Kabbara and Allen, 1999; Ward et al., 1998; 
Westerblad and Allen, 1991) and/or a reduction in the 
sensitivity of the contractile apparatus to calcium (Godt 
and Nosek, 1989; Westerblad and Allen, 1993). Both 
scenarios would result in impaired excitation-contraction 
coupling such that less force is generated for each indi-
vidual membrane excitation. 
A possible protective effect of testosterone against 
skeletal muscle fatigue was suggested when Bosco et al. 
(2000) investigated neuromuscular activity and hormonal 
profile following an acute resistance exercise session in 
male and female sprint athletes. Full squat power de-
creased by 10% at the end of the session in males only. 
EMG/power ratio calculated in the half squat test were 
decreased in both males and females, but only reached 
significance in males (p <0.05). Levels of circulating 
testosterone, cortisol and luteinising hormone were sig-
nificantly lower post exercise in males only, while a nega-
tive correlation (r = -0.61) was found between change in 
testosterone concentration and EMG/power ratio in half 
squat performance in both groups.  Bosco et al. (2000) 
suggested adequate testosterone levels may compensate 
for or offer protection against the effect of fatigue in fast-
twitch muscle fibres by ensuring a better neuromuscular 
efficiency (Bosco et al., 2000). 
We therefore propose, based on results of prior 
non-genomic testosterone research, that acute elevations 
in testosterone concentration (such as those during the 
female menstrual cycle) may be able to reduce or com-
pensate the effects of fatigue in fast-twitch fibres. Due to 
non-genomic rapid increases in intracellular calcium 
levels and increased mobilisation of calcium from the 
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sarcoplasmic reticulum, testosterone may reduce or pro-
tect against impaired excitation-contraction coupling 
during repeated high-intensity muscle contraction. How-
ever, gender differences in hormonal changes, notably 
testosterone following squat exercise reported by Bosco et 
al., (Bosco et al., 2000) suggest future research should 
investigate if there are indeed gender specific responses in 
non-genomic testosterone action.   
 
Specific importance of testosterone for female athletes 
Testosterone levels have often been difficult to accurately 
measure in females due to the combined challenge of both 
the naturally low levels of circulating testosterone cou-
pled with low sensitivity and precision of assays.  Previ-
ous studies have however shown that circulating testos-
terone fluctuates throughout the menstrual cycle (Judd 
and Yen, 1973; Sinha-Hikim et al., 1998). Serum total 
and free testosterone levels in the luteal and follicular 
phases are not significantly different from each other, but 
an approximate 30-45% pre-ovulatory increase in both 
total and free testosterone roughly three days prior to the 
luteinising hormone peak was recorded in two separate 
studies investigating testosterone levels across a full men-
strual cycle (Judd and Yen, 1973; Sinha-Hikim et al., 
1998). However, even though a clear peak in both total 
and free testosterone was shown in these two studies, no 
studies have yet to specifically investigate changes in 
muscle strength, explosive power or fatigue when testos-
terone levels are peaked, which could prove an important 
measure as previous studies have shown strong positive 
correlations with acute natural testosterone concentration 
and acute power performance such as counter-movement 
jump height. 
 
Influence of oral contraceptives 
Combined hormonal contraceptives prevent ovulation as 
their primary mechanism of action (Rivera and Yacobson 
et al., 1999). This elimination of ovulation also eliminates 
the natural peaking in testosterone prior to the luteinizing 
hormone surge. Oral estrogens ingested in common varie-
ties of the oral contraceptive pill, can have significant 
consequences on circulating free testosterone levels 
(Edwards and O'Neal, 2009; Raj et al., 1983; Rickenlund 
et al., 2004; Thorneycroft et al., 1999; Van der Vange et 
al., 1990; Wiegratz et al., 1995; 2003a). Oral estrogens 
can increase the levels of sex hormone binding globulin 
(Campagnoli et al., 1993; Thorneycroft et al., 1999; 
Wiegratz et al., 1995; 2003a), which binds to testosterone 
making it biologically unavailable thus reducing the ratio 
of circulating free testosterone to total testosterone. 
Progestin’s can also influence circulating testoster-
one levels in females, (Gordon et al., 1970) Medroxypro-
gesterone, a synthetic version of the naturally synthesized 
human progesterone (often used in oral contraceptives) 
decreases the production rate of testosterone, likely due to 
the inhibition of pituitary secretion of luteinizing hormone 
and may increase the rate of removal of testosterone from 
the circulation (Gordon et al., 1970) (Palatsi et al., 1984; 
Wiegratz et al., 2003b). Along with the elimination of the 
peak in testosterone during the cycle, and reductions in 
total testosterone concentration, oral contraceptives may, 
in our opinion, affect genomic and non-genomic actions 
of testosterone, reducing optimal hormonal physiology for 
elite female athletic performance. 
The potential impact of the menstrual cycle on an-
aerobic performance has received less attention than the 
impact on aerobic variables. There is a lack of consensus 
on whether sex hormone fluctuations have an influence on 
anaerobic performance, with some studies concluding  
performance is unaffected by menstrual cycle phase, 
(Doolittle and Engebretsen, 1972; Giacomoni et al., 2000; 
Lebrun, 1993; 1994; Lebrun et al., 1995) and others re-
porting differences in anaerobic performance variables 
with menstrual cycle phase (Davies et al., 1991; 
Masterson, 1999; Wearing et al., 1972). The strength of 
the research looking at anaerobic performance and sex 
hormones is faltered by a lack of experimental controls, 
including variation in the determination of cycle phase 
(hormonal assay vs. body temperature), unclear subject 
selection criteria, and differing measures of performance 
(sprinting vs. jumping vs. swimming and acute vs. re-
peated efforts). There is yet no published research on the 
effect of menstrual cycle hormones on anaerobic/power 
variables in elite female athlete populations.  
Studies in which oral contraceptive users were 
compared with eumenorrheic females have reported a 
trend towards lower strength across an oral contraceptive 
cycle compared with a natural cycle. As well, a complete 
reduction in the natural fluctuation of testosterone and 
strength often seen with a natural cycle has been shown in 
women using an oral contraceptive (Phillips et al., 1996; 
Sarwar et al., 1996). There is little research that has spe-
cifically looked at the effect of the menstrual cycle or oral 
contraceptives on explosive power in female athletes. 
However, one study examined team sport performance 
variables during an oral contraceptive cycle (Rechichi and 
Dawson, 2009), with the only significant difference  
found in drop jump height in the late withdrawal phase 
(end of the sugar pills), where a reduced drop jump height 
coincided with increased serum estrogen levels (Rechichi 
and Dawson, 2009). It is possible that changes may have 
occurred in performance variables in females with a natu-
ral menstrual cycle due to the fluctuations in circulating 
testosterone; however, although testosterone is known to 
reach a peak during the menstrual cycle, no study has 
specifically investigated athletic performance at this time. 
Furthermore, there are no studies available that have con-
ducted performance tests every day of the menstrual cycle 
to ensure all hormonal fluctuations are investigated. In 
spite of this, due to testosterone’s correlation with explo-
sive power and evidence of a non-genomic testosterone 
action in skeletal muscle, individual female athletes 
whose events require strength or power may benefit from 
using non-hormonal based contraceptive methods. 
 
Polycystic ovarian syndrome and other menstrual 
disorders: A physiological advantage? 
Previously, oligomenorrhea in exercising women was 
seen as a symptom of menstrual disorders, secondary in 
response to metabolic perturbations due to extreme en-
ergy deficit (often seen in endurance runners and associ-
ated with leanness) (Rosetta et al., 1998; Sanborn et al., 
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1982; Torstveit and Sundgot-Borgen, 2005). However, 
with the potential for oligomenorrhea to be associated 
with hyperandrogenism [particularly increased levels of 
testosterone outside (or within the higher range) of the 
physiological limits for normally menstruating women] 
many athletic women suffering from oligomenorrhea may 
not, as expected, present with symptoms of energy deficit. 
Therefore, our opinion is that the perception that female 
athletes who present with oligomenorrhea are most likely 
to be experiencing extreme energy deficit, may be un-
founded. 
Although research into the prevalence of hyperan-
drogenism and polycystic ovarian syndrome in athletic 
populations is scarce, the available data suggest that the 
most common diagnosis of menstrual disturbance in 
Olympic athletes (Hagmar and Berglund et al., 2009) and 
women in sports where muscle mass is advantageous or 
non-detrimental to performance (Lebrun, 1994; 
Masterson, 1999) is polycystic ovarian syndrome. It may 
be that women with polycystic ovarian syndrome or hy-
perandrogenism are inherently attracted to and succeed in 
athletic activities. This suggests that oligomenorrhea is 
also likely to be a polycystic ovarian syndrome or meta-
bolic syndrome symptom in athletic women, as opposed 
to an exercise-induced trait per se. We suggest that poly-
cystic ovarian syndrome may be a competitive advantage 
due to the proposed dual mechanism of testosterone 
(long-term effects on muscle strength and size, and a 
rapid acute effect on contractile efficiency).  
Further research is needed to confirm whether 
acute testosterone fluctuations seen during a natural men-
strual cycle or heightened levels seen in conditions such 
as polycystic ovarian syndrome are significant enough to 
result in a greater efficiency of the skeletal muscle to 
produce force/power. Polycystic ovarian syndrome or 
hyperandgrogenism could lead to a physiological advan-
tage for female athletes, especially those competing in 
athletic events that require rapid and/or forceful move-
ments. 
 
Non-genomic actions of estrogen 
While this review focuses on the specific role of non-
genomic testosterone action in skeletal muscle and its 
effects within the contractile compartment of skeletal 
musculature it is within the scope of this article to briefly 
discuss the potential effects of a subsidiary non-genomic 
action of another prominent sex hormone that fluctuates 
throughout the female menstrual cycle, estrogen. 
While ageing, muscle wasting and pathology re-
search support a role for estrogens in skeletal muscle, 
particularly in females it is likely that the prevention of 
strength loss through estrogen hormone replacement ther-
apy is likely a genomic or transcriptional mechanism 
rather than a rapid non-transcriptional mechanism. As this 
review is also focusing on the effects of testosterone on 
the contractile apparatus it seems pertinent to discuss 
those findings in rodent studies that indicate estrogen can 
influence the force generating capacity of skeletal muscle 
not by maintaining size of individual fibres but by main-
taining the integrity and ability of individual fibres to 
generate force. This idea is supported by Wattanaperm-
pool et al. (1999) who measured cross sectional area 
(CSA) and the peak isometric tension of isolated rat so-
leus muscle fibres 10 and 14 wk post ovariectomy. While 
CSA was not reduced following ovariectomy, CSA was 
significantly increased compared with non-ovariectomy 
controls at 14 wk, peak tension was significantly lower in 
ovariectomised rats compared with sham-operate controls 
in both 10-wk (~19%) and 14 wk (~20%) post ovariec-
tomy. These results show that fibres from ovariectomised 
rats were not weaker due to their smaller size but rather 
there was a deficit in the contractile apparatus likely due 
to the absence of estrogen that resulted in a reduced abil-
ity to produce force. 
Similarly to testosterone, non-genomic estrogen ac-
tion has been regularly identified in tissues other than 
skeletal muscle (Morley et al., 1992; Rubio-Gayosso and 
Sierra-Ramirez et al., 2000; Watson et al., 2008; Younglai 
et al., 2005). The most regularly reported non-genomic 
effect of androgen exposure is a rapid (within seconds) 
enhancement in intracellular calcium concentration 
(Ceballos et al., 1999; Morley et al., 1992; Vicencio et al., 
2006; Watson et al., 2008). Estrogen is not exempt from 
this effect and it was originally demonstrated in chicken 
granulosa cells subjected to 17-β estradiol, that there was 
an immediate (less than 5 s) 4-8 fold increase in calcium 
concentration in all of the 76 cells exposed [67]. Estrogen 
receptors have also been found to interact with a G-
protein on the cell membrane of osteoblasts leading to a 
rapid increase in intracellular Ca2+ concentration due 
distinctly to increased Ca2+ mobilisation from the endo-
plasmic reticulum and the formation of IP3 demonstrating 
a similar mechanistic pathway as that shown during the 
mobilisation of intracellular Ca2+ from the sarcoplasmic 
reticulum in skeletal muscle cells by rapid testosterone 
action. At this time no research has specifically investi-
gated a non-genomic action of estrogen in skeletal mus-
cles at either the molecular or whole muscle level. 
Again, like testosterone, estrogen has demonstrated 
possible positive effects in skeletal muscle, in particular 
producing positive effects within the contractile machin-
ery and even though these effects have been seen be in the 
presence (hormone replacement therapy) or absence (age-
ing/ovariectomy) of constant exposure or non-exposure to 
estrogen (17-β estradiol), the non-genomic actions of 
estrogen in tissues other than skeletal muscle are similar 
to those demonstrated by testosterone in skeletal muscle 
cells. Therefore research is required to investigate a pres-
ence of a non-genomic action of estrogen in skeletal mus-
cles and determine its ability to modulate force-generating 
processes. It may therefore be likely that both testosterone 
and estrogen are able to enhance myosin and actin bind-
ing processes due to modulations in calcium mobilisation, 
resulting in a greater force and/or velocity of contraction 
during acute changes in their concentrations. 
 
Conclusion 
 
At this time, there is small evidence of non-genomic tes-
tosterone action in human skeletal muscle and the specific 
mode of action, as well as testosterone’s practical impor-
tance to athletic competition are yet to be identified. Some 
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evidence points towards direct non-genomic activation of 
calcium-mediated events in skeletal muscle cells, which 
may modulate significant physiological responses such as 
the acute modulation of force in individual fibres and 
acute prevention or protection against calcium-mediated 
fatigue. These responses are likely complex and mediated 
by interplay between testosterone and second messengers 
IP3 and calcium, which ultimately may result in simulta-
neous non-genomic and genomic modulations of skeletal 
muscle events. However, more research is needed to elu-
cidate the potential membrane receptor involved, as well 
as the second-messenger pathway, the resulting action at 
the single-cell level and the transference of testosterone to 
whole muscle significance. Due to fluctuations in testos-
terone during the female menstrual cycle, research should 
also aim to identify if there are genuine gender differ-
ences in the response or mechanism of non-genomic ac-
tion of testosterone in skeletal muscle. There may be a 
physiological advantage for female athletic performance 
during particular phases of the menstrual cycle. As well, 
polycystic ovarian syndrome and similar hyperandrogen-
ism disorders may be a physiological advantage for spe-
cific athletes. Research to date suggests the main physio-
logical function of non-genomic testosterone action in 
skeletal muscle is the enhancement of force production 
particularly in fast twitch fibres; however the actions are 
likely multifaceted and further research is needed to pro-
vide evidence of a whole body performance effect in 
humans. 
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Key points 
 
• Non-genomic calcium mediated events activated by 
testosterone have been identified in skeletal muscle 
cells. 
• The non-genomic action originates at the cell mem-
brane, is rapid in onset and is directed by second 
messengers’ calcium and IP3. 
• A possible action of non-genomic testosterone may 
be the initiation of a more efficient contraction 
through the mobilisation of calcium from the SR re-
sulting in greater force production or velocity of 
contraction in fast twitch fibres. 
• Physiologically, females with menstrual disorders 
that cause hyperandrogenism may have a perform-
ance advantage in events that require great force or 
power production. 
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